U.S. Entertainment Stock News

Brady (BRC) is back on many investors’ screens after a recent shift in its share performance, with the stock flat over the past day but showing mixed moves over the past month and over the past 3 months. See our latest analysis for Brady. With the share price at $85.99, Brady’s recent 30 day share price return of 10.73% decline contrasts with a 9.33% share price gain year to date and a 21.91% total shareholder return over the past year. This suggests momentum has cooled after a stronger...

Experis, a ManpowerGroup brand, recently launched its EXCELERATE AI enterprise AI agent services portfolio and Enterprise AI Services Suite, partnering with SoundHound AI to deploy and manage conversational AI agents at scale for large organizations, initially focusing on sectors such as US healthcare. This move extends ManpowerGroup’s role beyond technology staffing into building and orchestrating AI-powered automation for clients, potentially deepening relationships and expanding...

Zions Bancorporation, N.A. recently became the focus of a securities fraud investigation after disclosing apparent misrepresentations and contractual defaults on two commercial and industrial loans in its California Bank & Trust division, prompting full provisioning and significant charge‑offs. At the same time, Zions is hosting a fraud prevention conference and has taken a lead role arranging a US$490 million credit facility for Varex Imaging, underscoring its dual position as both a risk...

On March 10, 2026, Markel Insurance appointed Kristen Dardia as Head of Portfolio Analytics for the US and Bermuda, tasking her with leading advanced analytics, technical pricing, and portfolio management after nearly two decades in actuarial science, analytics, and business strategy. Her track record embedding analytics into underwriting and portfolio decisions could meaningfully influence how Markel Group refines risk selection and pricing across its specialty insurance operations. Next,...

If you are wondering whether Sterling Infrastructure's recent run leaves any value still on the table, a good starting point is understanding what the current share price is really implying. Sterling Infrastructure recently closed at US$425.51, with returns of 3.4% over the last 7 days, a 2.8% decline over 30 days, 33.3% year to date and 260.5% over 1 year, alongside very large 3 year and 5 year gains. Recent attention on Sterling Infrastructure has largely centered on its sharp share price...

Snowflake recently presented at the HIMSS 2026 Global Health Conference and the 3rd Billington State and Local CyberSecurity Summit, underscoring its push into healthcare and public-sector data and security use cases. These appearances come as Snowflake highlights over 430 new AI features and deep partnerships with Anthropic, Google Cloud, and OpenAI, reflecting a broadening role in enterprise AI workloads. Now we’ll examine how Snowflake’s rapid rollout of hundreds of new AI capabilities...

Blue Bird (BLBD) has drawn fresh investor attention after analysts raised their consensus earnings estimate, even though they expect quarterly earnings per share of $0.81 to be below the level reported in the prior year. See our latest analysis for Blue Bird. The latest 1 day share price return of 1.19% and 7 day return of 2.00% sit against a softer 30 day share price return of 5.38%. Total shareholder returns of 56.00% over one year and 165.42% over three years point to momentum that has...

CSX expanded its Select Site initiative by awarding its designation to 21 new rail served properties across 10 states. Owens Corning announced a large manufacturing investment at a CSX Silver Select Site in Alabama, tied to about 100 new skilled jobs. This development reflects fresh industrial interest in CSX served locations, beyond recent discussions focused on valuation, margin outlook, and service metrics for NasdaqGS:CSX. For investors tracking NasdaqGS:CSX, this move adds a fresh...

NIKE (NKE) is back in focus after Barclays shifted to a more positive stance on the stock, citing operational progress, cleaner financial metrics, and tighter management discipline ahead of key upcoming earnings. See our latest analysis for NIKE. Despite Barclays turning more positive, the recent 30 day share price return of a 12.69% decline and the 90 day share price return of a 16.09% decline show momentum has been weak, and the 1 year total shareholder return of a 22.93% loss points to an...

Planet Labs PBC (PL) has drawn investor attention after a recent double digit one-day move, adding to gains over the past month and past 3 months, prompting a closer look at its current setup. See our latest analysis for Planet Labs PBC. That 10.1% 1 day share price return and 20.8% 30 day share price return feed into a much bigger move, with momentum reinforced by a 64.4% 90 day share price return and a very large 1 year total shareholder return. If you are interested in what else is moving...

Insulet (PODD) is in focus after disclosing an internal tubing defect in certain Omnipod 5 Pod lots, prompting a voluntary Medical Device Correction and free replacements. Production and new patient starts are expected to continue. See our latest analysis for Insulet. The tubing defect news has landed against a weak recent share price backdrop, with the 90 day share price return at a 20.4% decline and the 1 year total shareholder return at an 11.5% loss. This suggests that momentum has been...

In March 2026, Aldeyra Therapeutics reported that the FDA issued a Complete Response Letter for its reproxalap dry eye disease NDA, citing insufficient and inconsistent evidence of efficacy despite no safety or manufacturing concerns. An important nuance is that the FDA did not request new trials, instead urging Aldeyra to clarify why certain studies failed and where reproxalap might work best. We’ll now examine how the FDA’s efficacy concerns and lack of requested new trials reshape...

In early 2026, a joint SONAR and Ryder System report showed tender rejection rates climbing to nearly 14.3% in early February, reaching levels last seen during the pandemic and pointing to tightening trucking capacity. This spike in rejection rates hints at a shifting freight balance that could influence pricing power and operational conditions for logistics providers like Ryder. We’ll now examine how this jump in tender rejection rates could influence Ryder’s existing investment narrative...

Evercore recently expanded its healthcare and biotechnology advisory platform, adding senior biotechnology-focused banker David Ke to its equity capital markets group in New York and featuring senior healthcare banker Bennett Blau at the 2026 Life Science Intelligence Summit. These moves highlight Evercore’s push to deepen sector expertise and client reach in biotechnology and life sciences at a time when healthcare capital formation remains a key focus for global investment banks. Now we’ll...

In recent days, IBM has unveiled an industry-first quantum-centric supercomputing reference architecture, expanded its AI collaboration with NVIDIA, and completed an approximately US$11.00 billion acquisition of data-streaming firm Confluent to strengthen its hybrid cloud and AI data platform. Together, these moves deepen IBM’s role at the intersection of quantum computing, high-performance AI infrastructure, and real-time enterprise data, potentially reshaping how large organizations build...

Vertiv Holdings Co (NYSE:VRT) has partnered with NVIDIA to deliver converged infrastructure for AI factory deployments. The collaboration introduces simulation ready digital power and cooling assets into NVIDIA's Vera Rubin DSX AI factory reference design and Omniverse DSX Blueprint. The goal is to speed up and de risk large scale AI projects through validated, repeatable, digitally coordinated infrastructure modules. For investors tracking AI infrastructure, this partnership provides...

Impinj recently entered privately negotiated agreements to repurchase approximately US$40.2 million of its 1.125% convertible notes due 2027 for cash, leaving about US$57.3 million outstanding after the March 16, 2026 closing. This sizable debt repurchase alters Impinj’s capital structure and could influence how investors assess its balance sheet strength and financial flexibility. Next, we’ll examine how Impinj’s sizable convertible note repurchase affects its existing investment narrative...

Earlier this month, Tenaya Therapeutics announced a research collaboration with Alnylam Pharmaceuticals to validate up to 15 gene targets for cardiovascular disease, receiving an upfront US$10 million payment, cost reimbursement over two years, and eligibility for as much as US$1.13 billion in development and commercial milestones. The collaboration highlights Alnylam’s effort to extend its RNAi platform into cardiovascular indications while outsourcing early target validation to a...

If you are wondering whether Rhythm Pharmaceuticals at around US$87.68 is still reasonably priced after its run, you are not alone. This article takes a closer look at what that level might mean for value focused investors. The stock has seen a 5.7% decline over the past week and a 10.6% decline over the last month, even after a 67.7% return over the past year and a very large gain over three years of about 4x. Recent coverage has highlighted investor interest following these sizeable multi...

T-Mobile US (NasdaqGS:TMUS) is collaborating with NVIDIA to pilot distributed edge AI infrastructure across its 5G network. The pilot aims to support real-time AI workloads for use cases such as smart cities, utilities, facility management, and industrial safety. This move extends T-Mobile's role from a traditional wireless carrier to a platform provider for enterprise-grade edge AI computing. T-Mobile US, trading at around $213.35, sits at the center of a broad shift where connectivity and...

Renasant (RNST) has drawn fresh attention after its recent share performance, with the stock down about 13% over the past month and 5% over the past 3 months, despite positive 1 year total returns. See our latest analysis for Renasant. The recent 13.4% 1 month share price decline, on top of a 5.4% 3 month share price fall, contrasts with Renasant's 4.6% 1 year total shareholder return. This suggests near term momentum is fading even as longer term investors remain modestly ahead. If you are...

AbbVie (NYSE:ABBV) is facing a revived whistleblower lawsuit alleging violations of the U.S. False Claims Act tied to federal drug pricing. The case brings renewed attention to AbbVie’s pricing practices within government programs and its potential legal exposure. Separately, AbbVie has entered a new multi year antibody discovery collaboration with Alloy Therapeutics. The Alloy agreement focuses on antibody discovery platforms intended to support AbbVie’s work on biologics and difficult drug...

Procter & Gamble (PG) is back in focus after rolling out premium upgrades across flagship brands, including Pampers AMORE diapers with five layer protection and higher absorbency, as well as deeper cleaning Swiffer PowerMop pads. See our latest analysis for Procter & Gamble. Despite the stream of premium launches across Pampers, Swiffer, Mr. Clean and BEVEL, the 30 day share price return of Procter & Gamble is a 5.37% decline, while its year to date share price return of 6.83% and 5 year...

Earlier this month, Abbott Laboratories reported that its FreeDM2 randomized controlled trial found the FreeStyle Libre continuous glucose monitoring system improved HbA1c, time-in-range, and quality-of-life outcomes for people with Type 2 diabetes on basal insulin, while also launching its latest XIENCE Skypoint coronary stent in India to support treatment of complex heart blockages. Together, these advances in diabetes care and cardiovascular devices highlight Abbott’s push to deepen its...